'Unprecedented' collaboration news not what Auris ordered
On the day after Swiss biotech Auris Medical Holding (Nasdaq: EARS) announced its latest failure in an otolaryngology trial, the US start-up that claims to be a leader in hearing therapeutics has announced a collaboration with a big-name drugmaker.
Decibel Therapeutics, founded by hearing experts and launched in late 2015 by Third Rock Ventures with SR One, the independent corporate healthcare venture capital fund of UK pharma major GlaxoSmithKline (LSE: GSK), has teamed up with US biotech company Regeneron (Nasdaq: REGN).
The collaboration, which gives Decibel access to Regeneron’s scientific expertise rather than handing over rights to the larger company for a certain candidate, is aimed at discovering and developing therapeutics for hearing loss and tinnitus.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze